This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
New Phase II data show vast majority of patients experiencing no relapses or disability progression
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated
